ArticleDigestive diseases and sciences2025
E3 Ubiquitination Ligase MYLIP Mediates the NKRF/SLC25A34 Axis to Suppress Malignant Progression in Colorectal Cancer.
Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- PRRX2-CNTN3 axis promotes epithelial-to-mesenchymal transition and metastasis in colorectal cancer.Cell division · 2026Article
- Construction of a Mitochondria-Related Gene Diagnostic Model Based on Integrated Multiomics Data and Functional Validation of ANK2 as a Key Regulator in Colorectal Cancer.International journal of genomics · 2026Article
- Identification of Key Biomarkers and Immune Microenvironment Features in Ulcerative Colitis: An Integrated Analysis Using WGCNA and Multiple Machine Learning Algorithms.Journal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe SLC25 family of transport proteins has been implicated in colorectal cancer (CRC) tumorigenesis. However, the potential role of SLC25A34 in CRC remains unclear. This study was designed to elucidate the role and mechanism of SLC25A34 in CRC.
methodsBy screening differentially expressed genes in the GSE141174 and GSE184093 datasets and colorectal adenocarcinoma in the GEPIA database, we identified SLC25A34 as an important gene in CRC. Expression of SLC25A34, NKRF, and MYLIP in CRC cells was examined by RT-qPCR and western blot analysis. CCK-8, colony formation, TUNEL, and Transwell assays were used to detect CRC cell proliferation, growth, mobility, and apoptosis. Mice were injected subcutaneously or intravenously to explore the effects of MYLIP, NKRF, and SLC25A34 on xenograft formation and lung metastasis. The underlying molecular mechanisms were further investigated using RT-qPCR, western blot, immunoprecipitation, protein stability, and ubiquitination assays.
resultsSLC25A34 was reduced in CRC tissues and cells, and overexpression of SLC25A34 repressed the malignant phenotype of CRC cells. NKRF inhibited SLC25A34 transcription in CRC cells, and silencing SLC25A34 overturned the suppressive effects of NKRF knockdown on cell proliferation, growth, and mobility. Overexpression of MYLIP in CRC cells inhibited NKRF expression by degrading NKRF to activate SLC25A34 transcription and inhibit xenograft formation and lung metastases.
conclusionOur study revealed a novel role for MYLIP-mediated NKRF ubiquitination and degradation in the induction of SLC25A34 transcription, which may act as a therapeutic target for CRC.
Indexed as
Identifiers
39661280What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.